Continuing treatment for spinal muscular atrophy (SMA) is essential and should not be considered elective, or be delayed or interrupted if possible, despite the healthcare limitations imposed by the COVID-19 pandemic.  These are the main recommendations given unanimously by a panel…
Mutations in genes that interact with the SMN protein, which is lacking or present at low levels in spinal muscular atrophy (SMA) patients, are not able to explain the wide range of severity found in all forms of the disease, a study reports. The study, “Analysis…
Researchers in Germany have found that newborn screening for spinal muscular atrophy (SMA) would likely be beneficial, based on evidence that early diagnosis and treatment leads to better motor development such as walking and sitting independently, less need for permanent ventilation, and lower mortality. The…
Get regular updates to your inbox.